Clinical and Metabolic Responses to Magnesium Supplementation in Women with Polycystic Ovary Syndrome.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.

The present study aimed to investigate the effect of magnesium supplementation on metabolic profiles and levels of sex hormones in women with PCOS.

To assess biochemical indicators, a venous blood sample was taken after an overnight fasting.

Why It Was Studied

The mean age of study participants was 26.4 years.

Who Took Part

The abstract describes 60 women taking part.

By PubMed's age tags, the people studied were young adults, adults and middle-aged adults, women only.

In this parallel randomized, double-blind, placebo-controlled clinical trial, 60 women with PCOS aged 20-45 years were recruited.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and parallel-group study.

The women were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

Blinding on both sides kept the women and researchers unaware of who received Vitamin D, K2, Magnesium and Zinc.

Some women received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.

The Vitamin D, K2, Magnesium and Zinc group and the comparison group ran side by side rather than switching.

What Was Measured

The subject headings attached to it are Dietary Supplements, Luteinizing Hormone, Magnesium and Polycystic Ovary Syndrome.

The authors tagged it with the keywords Insulin, Metabolic profiles, PCOS, Sex hormones and Supplementation.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 60 women.

The publication is from 2020 (Biological trace element research), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.